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WHAT THIS PAPER ADDS
 The ﬁndings of this study suggest that the increased prevalence of chronic obstructive pulmonary disease (COPD) in patients with
an abdominal aortic aneurysm (AAA) is independent from smoking. Along with other observed parallels between AAA and COPD,
results of this study hint at a predetermined cause of these diseases, warranting further investigation of common genetic,
inﬂammatory and remodelling pathways. Identiﬁcation of common mechanistic pathways might be highly relevant for future AAA
and COPD research and research collaboration initiatives. The burden of undetected COPD is relevant to those involved in the care of
AAA patients.a r t i c l e i n f o
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Objectives: It is currently unclear whether the parallels between abdominal aortic aneurysms (AAAs) and
chronic obstructive pulmonary disease (COPD) are explained by common risk factors alone, such as
cigarette smoking, or by a predetermined cause. Given the persistent controversy with regard to the
association between AAA and COPD, we studied this association in depth.
Methods:We conducted a caseecontrol study comparing patients with a small AAA (maximum infrarenal
diameter 35e50 mm, n ¼ 221) with controls diagnosed with peripheral artery disease (PAD, n ¼ 87). The
controls were matched to the cases for lifetime cigarette smoking. Pulmonary function was measured by
spirometry, and all subjects completed a questionnaire on medical history and smoking habits (current,
former and never smokers).
Results: Aneurysm patients were similar to controls with respect to gender (p ¼ 0.71), lifetime cigarette
smoking (39 vs. 34 pack years, p ¼ 0.23) and history of cardiovascular disease (45% vs. 55%, p ¼ 0.12).
Aneurysm patients had more airway obstruction (forced expiratory volume in 1 s/forced vital capacity
(FEV1/FVC) (0.69  0.12 vs. 0.78  0.11, p < 0.001)), which was most pronounced in never smokers
(0.73  0.07 vs. 0.86  0.07, p < 0.001). COPD was more prevalent in aneurysm patients (44%; 98/221)
than in controls (20%; 17/87) (adjusted odds ratio (OR) 3.0; 95% conﬁdence interval (95%CI) 1.6e5.5,
p < 0.001). In particular, a major proportion of AAA patients was newly diagnosed with COPD; only
40 of 98 patients (41%) with COPD (mild, moderate or severe/very severe) were known before with
obstructive pulmonary defects and received treatment.
Conclusions: This study conﬁrms an association between AAA and COPD and shows that this association
is independent from smoking. Findings also demonstrate that COPD is under-diagnosed in AAA patients.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.nt of Surgery, K-6-R, P. O. Box 9600, 2300RC Leiden, The Netherlands. Tel.: þ31 (0) 715261689.
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rysms (AAAs) and chronic obstructive pulmonary disease (COPD),
both with regard to risk factors as well as to the underlying path-
ophysiology. Both diseases have a particularly strong relationship
with smoking, and smoking cessation appears to be the principal
disease-modifying intervention.1e3 Moreover, their pathophysio-
logic bases are best described as a persistent pro-inﬂammatory
response that is associated with proteolysis and excess matrix
turnover.2e5
A relation between AAA and COPD was ﬁrst suggested by
Cronenwett et al., who reported in 1985 that COPD was more
common in patients with a ruptured aneurysm.6 Several succes-
sive reports also indicated an association between AAA and COPD,
although the by far largest study in aneurysm patients rejected an
independent association (a summary of the reports is found in
Table 1).7e13 Moreover, interpretation of these reports is compli-
cated by considerable heterogeneity in outcome measures, deﬁ-
nitions and control populations in these studies. In particular,
a relation between AAA and COPD that is beyond that of smoking
alone remains unclear.
We performed pulmonary testing in a cohort of patients with
a small abdominal aneurysm and compared the results with
a control group of patients with clinical peripheral artery disease
(PAD). As there is a large overlap in risk factors, in particular the
predominance of smoking, and patient characteristics between
AAA and PAD populations, it was reasoned that this group consti-
tuted themost optimal control group.3,14 With this study, we aim to
test whether the suggested relationship between AAA and COPD
extends beyond smoking alone.Table 1
Overview of previous reports on the relation between abdominal aortic aneurysm and c
Study Number
AAA
Population Method De
Cronenwett 19856 67 AAA patients selected
for non-surgical
management
Spirometry Mi
FEV
sev
Bengtsson 19917 39 AAA screening and
general population
controls
Spirometry Un
Smith 199310 219 AAA screening
population, general
population controls
Unknown Un
Laarhoven 19938 36 COPD-patients COPD by hospital
record
Mi
em
FEV
Lindholt 19989 139 AAA screening
population, AAA in
COPD vs. AAA in
non-COPD
COPD by hospital
record
As
Wo
Or
Lederle 200013 1917 AAA screening
population
COPD as a
questionnaire item
Un
Sakamaki 200211 118 Japanese AA patients,
with present AAA or
TAA, without AA with
CAD, without both
Spirometry with
reversibility testing
Air
dis
< 0
Fowkes 200612 89 AAA surgical waiting-list
and general population
controls
Spirometry
max of three
measurements,
Mo
cla
Cronenwett et al.6 were the ﬁrst to report on this relation, although they were rather focu
respect to the used deﬁnitions, measures and analyses. However, implication of these stu
and control population, in particular with respect to smoking behaviour.Methods and Material
Design
The study enrolled patients with a small infrarenal AAA, who
participated in a larger study, the Pharmaceutical Aneurysm Sta-
bilisation Trial (PHAST trial http://www.trialregister.nl/trialreg/
admin/rctview.asp?TC¼1345).
This multicentre trial studied whether 18months of doxycycline
treatment reduced aneurysm progression in 286 randomised
Caucasian patients with small AAA (35e50 mm). The trial was
conducted between January 2009 and June 2011 in 14 Dutch
hospitals (manuscript submitted). Primary approval for the PHAST
trial and this sub-study was obtained from the Medical Ethical
Review Board of the Leiden University Medical Center.
The presence of AAA and maximum aortic diameter size was
assessed by single-observer ultrasound measurement of the ante-
roposterior diameter (Siemens P50, 1.67e4.0 MHz phased array
transducer, Siemens Medical Systems, Mountain View, Ca, USA.).
Included were all patients with a conﬁrmed AAA sized 35e50 mm.
All measurements were performed at baseline, that is, immediately
before randomisation.
The control population consisted of patients with established
PAD referred to the outpatient department of vascular surgery at
the Leiden University Medical Center and the Deventer Hospital. All
patients underwent an abdominal ultrasound to exclude an aortic
aneurysm (i.e., infrarenal aortic diameter <25 mm). PAD was
deﬁned by a history of manifest intermittent claudication with an
ankleebrachial index (ABI)< 0.9, or by a history of lower-extremityhronic obstructive pulmonary disease.
ﬁnition Conclusion Limitation
ld to moderate
1  50% pred.,
ere FEV1 < 50% pred.
Obstructive pulmonary
disease predictive for
aneurysm rupture
Relation with aneurysm
rupture, no conclusions
on non-ruptured aneurysm
known Smokers with affected
lung function are at risk
for AAA
Unclear deﬁnitions of
pulmonary function,
general population as
control
known A relation between AAA
and COPD
Unclear deﬁnition of
pulmonary function,
general population as
control, no adjustment
for smoking
ld or severe
physema,
/VC < 55%
High prevalence of AAA
in COPD patients
No control population,
no statistical analysis
deﬁned by
rld Health
ganization
Association caused by
medication and
cardiovascular history
COPD underestimation
without spirometry
testing. No adjustment
for smoking
known No association between
AAA and COPD after
adjustment for smoking
Questionnaires
insufﬁcient to detect
COPD
way obstructive
ease FEV1/FVC
.70
AAA risk factor for COPD Patients at high surgical
risk, exclusion of
currently smoking
patients and patients
treated for COPD
diﬁed GOLD
ssiﬁcation
Association, independent
of cigarette smoking and
cardiovascular history
Signiﬁcant differences
between cases and
controls on co-variates
smoking and cardiovascular
disease
sed on aneurysm rupture. Overtime, these studies show an increase in quality with
dies is complicated by considerable heterogeneity in outcome measures, deﬁnitions
Table 2
Patient characteristics of cases with abdominal aortic aneurysm and controls.a
PAD n ¼ 87 AAA n ¼ 221 p
Age 69  9 71  7 0.032
Male gender 85% 87% 0.71
Body height (cm) 175  8 175  8 0.42
Body weight (kg) 80  13 84  14 0.014
BMI 26.2  3.4 27.4  3.7 0.013
Smoking 0.029
Current 38 (44%) 66 (30%)
Former 39 (45%) 132 (60%)
Never 10 (11%) 23 (10%)
Pack years 34  27 39  31 0.23
DM 25 (29%) 32 (15%) 0.006
MI 23 (27%) 62 (28%) 0.89
Stroke 5 (6%) 11 (5%) 0.79
TIA 12 (14%) 20 (9%) 0.21
PAOD 87 (100%) 53 (24%) <0.001
All CVD (other than PAOD) 46 (55%) 98 (45%) 0.12
BMI; body mass index, DM; diabetes mellitus, MI; myocardial infarction, TIA;
transient ischaemic attack, PAD; peripheral artery disease, CVD; cardiovascular
disease.
a Data are presented as means  SD except for percentages (%) and p-values are
calculated using logistic regression. Bold p-values indicate a signiﬁcant difference
between AAA and PAD groups.
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lung surgery or aneurysmal diseases (i.e., an aneurysm on other
locations, e.g., the popliteal artery) were excluded. Because all
patients in the AAA group were between the ages of 50 and 89
years, only controls older than 50 years were included.
Prior tomeasurement of respiratory functions, the controls were
matched to the cases for lifetime cigarette smoking (group
matching). Matching was performed for four categories of smoked
pack years (PYs) (non-smokers (0 PY), 1e20 PY, 21e40 PYand more
than 40 PY) based on the frequency distribution of the PHAST
cohort.
Measurements
Eligibility was based on the patients’ medical records, and all
patients were interviewed about smoking habits, presence of
a diagnosis of COPD and history of cardiovascular disease. Smoking
status was deﬁned by the three categories of current, former and
never smokers. Lifetime cigarette consumption was analysed by
PYs (number of years smoked * average number of daily smoked
cigarettes/20). Referral to or treatment by a physician for COPD was
regarded as a previous diagnosis of COPD. Questions on cardio-
vascular history included myocardial infarction, cerebrovascular
accident or transient ischaemic attack, PAD and medication for
hypertension or diabetes mellitus. Body mass index (BMI) was
calculated as kg m2.
Pulmonary function was measured by spirometry in all partici-
pants with standardised, portable equipment (Microlab 3500,
MicroMedical Ltd, CA, USA). Measures of respiratory functions con-
sisted of forced expiratory volume in 1 s (FEV1), forced vital capacity
(FVC) and FEV1/FVC ratio. Published prediction equationswere used
to calculate the percentage of predicted FEV1 for each participant
(pFEV1%). The maximum of three repeated respiratory tests was
used in the analysis. A modiﬁcation of the Global Initiatives for
Chronic Obstructive Lung Disease (GOLD) deﬁnitional criteria was
used to classify subjects into the mutually exclusive categories of
severe/very severeCOPD (FEV1/FVC<0.7 and FEV1<50%predicted),
moderate COPD (FEV1/FVC <0.7 and FEV1 50% to <80% predicted)
and mild COPD (FEV1/FVC <0.7 and FEV1 80% predicted).15
Statistical analysis
Baseline data on respiratory functioning of 221 patients of the
PHAST trial were available. Calculation of the sample sizewas based
on the assumption that a 15% difference in mean FEV1 is clinically
relevant.12 To detect a differencewith a level of 0.05 and 90% power,
90 control patients were required.
The analysis was carried out by using Statistical Package for
Social Sciences (SPSS) version 17 for Windows (SPSS Inc., Chicago,
IL, USA). Data are presented as means  standard deviation (SD).
The patient characteristics including gender, age, smoking history,
BMI and cardiovascular risk factors were systematically recorded
and compared descriptively. Continuous variables were analysed
with the t-test and categorical variables with the chi-square test.
We used linear regression analysis to estimate differences in
outcome measures between the two groups. Multiple logistic
regression analysis was performed to ascertain whether chronic
obstructive airway disease was independently associated with the
presence of an AAA, compared with gender, age, smoking status,
presence of diabetes mellitus and a history of cardiovascular
diseases. Differences in change of aneurysm growth parameters
were assessed by repeated measurements analysis using linear
mixed models with a random intercept and slope per patient. To
assess whether growth rates were comparable between patients
with and without COPD, or within COPD disease stages, interactionterms between the disease stage and aneurysmal diameter were
used. All tests were two-tailed; p-values smaller than 0.05 were
considered to be statistically signiﬁcant.Results
Our study population consisted of 221 patients with an AAA
and 87 control patients with PAD without an AAA. The demo-
graphic and clinical characteristics of the two groups are outlined
in Table 2.
Aneurysm and control groups were similar with respect to
gender (p ¼ 0.71), lifetime cigarette smoking (39 vs. 34 pack years,
p ¼ 0.23) and history of cardiovascular disease (45% vs. 55%,
p¼ 0.12). The percentage of current smokers was higher in the PAD
patient group than in those with AAA (45% vs. 30%, p ¼ 0.029). AAA
patients were slightly older (71 vs. 69 years, p ¼ 0.03) and heavier
(BMI 27.4 vs. 26.2 kg m2, p ¼ 0.01) and were less frequently
diagnosed with diabetes mellitus (15% vs. 30%, p ¼ 0.006).
Signiﬁcant differences in indices of airway obstruction were
found (Table 3). The mean FEV1/FVC ratio was signiﬁcantly reduced
in aneurysm patients compared with controls (0.69 vs. 0.78,
p < 0.001). This reduced FEV1/FVC ratio in AAA patients was
consistently found in all three smoking cohorts, current (0.69 vs.
0.75, p¼ 0.013), former (0.68 vs. 0.79, p< 0.001) and never smokers
and most pronounced in never smokers (0.73 vs. 0.86, p < 0.001).
No signiﬁcant differences were found in FEV1 and pFEV1%
measures. In contrast, aneurysm patients had a signiﬁcantly larger
FVC (3.23 vs. 3.46, p ¼ 0.024). No relationship was found between
annual aneurysm expansion rates in patients with COPD
(2.3mmyear1) and thosewithout (2.5mmyear1) (p¼ 0.20) (data
not shown).
Classifying the results according to the GOLD criteria revealed
that COPD is more prevalent in aneurysm patients (98/221; 44%)
than in PAD patients (17/87; 20%). The unadjusted odds ratio of
aneurysm patients for COPD is 3.3 (conﬁdence interval 95% (CI95%)
1.8e5.9, p < 0.001), and 3.0 (95%CI 1.6e5.5, p < 0.001) when
adjusted for age, gender, smoking and presence of diabetes mellitus
and a history of cardiovascular disease. In particular, a major
proportion of aneurysm patients was newly diagnosed with COPD;
only 40 of 98 patients (41%) with COPD (mild, moderate or severe/
Table 3
Spirometry outcome measures in cases with abdominal aortic aneurysm and
controls.a
PAD n ¼ 87 AAA n ¼ 221 p
FVC (L) 3.23  0.78 3.46  0.83 0.024
FEV1 (L) 2.50  0.69 2.39  0.71 0.21
FEV1 % predicted 84.0  17.8 80.4  19.0 0.13
FEV1/FVC ratio 0.78  0.11 0.69  0.12 <0.001
Current smokers 0.75  0.11 0.69  0.14 0.013
Former smokers 0.79  0.10 0.68  0.12 <0.001
Never smokers 0.86  0.07 0.73  0.07 <0.001
FVC; forced vital capacity, FEV1; forced expiratory volume in 1 s, L; litre. FVC is
slightly increased in aneurysm patients.
Mean FEV1/FVC ratio is signiﬁcantly reduced in aneurysm patients compared with
controls, most pronounced in never smokers.
a Data are presented as mean  SD.
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defects and received treatment. (Fig. 1)
Discussion
This study demonstrates an increased prevalence of obstructive
pulmonary disease in patients with an AAA, a relationship that
appears independent from smoking. Our ﬁndings clearly support
the longstanding notion of an association between AAA and
obstructive airway disease. Although amajor proportion of COPD in
aneurysm patients is most likely smoking-induced, our results
suggest a relationship that is beyond that of smoking alone, as
clearly illustrated by spirometry results in never smokers. Findings
from this study also show that obstructive pulmonary disease often
remains unrecognised in aneurysm patients.
In 1985, Cronenwett et al. reported an association between
rupture of AAAs and obstructive pulmonary disease.6 Later reports
extended this notion, and described a generally increased preva-
lence of COPD in AAA patients, and of aneurysmal disease in COPD
patients.7e12 Unfortunately, interpretation of these studies is
hampered by methodological shortcomings such as identiﬁcation
of COPD on the basis of medical records or questionnaires, which
are known to underestimate the presence of pulmonary
disease.16,17 Moreover, the implication of the studies is complicated
by considerable heterogeneity in outcome measures, deﬁnitions
and control populations. Whether the presumed association is
dominated by smoking as the primary risk factor for both diseases
remains unclear. In addition, ﬁndings from these studies are notno COPD
n=123 (56%)
known COPD (all)
n=40 (18%)
unknown COPD 
(moderate/severe/very severe)
n=27 (12%)
unknown COPD (mild)
n=31 (14%)
Figure 1. Distribution of chronic obstructive pulmonary disease in AAA patients after
spirometry. Of 221 patients with AAA, a total of 98 (44%) patients had COPD, as
determined by spirometry and deﬁned by the GOLD classiﬁcation. 40 patients were
previously diagnosed and treated for COPD (all stages of GOLD-classiﬁcation). An
additional 27 patients were newly identiﬁed with moderate or severe/very severe
COPD and mild COPD was found by spirometry in 31 patients.supported by the largest study in AAA patients thus far (the
Veterans Affairs Aneurysm Detection and Management (VA) study)
where the association between COPD and AAA was lost after
adjustment for smoking.13 The reason for this apparent discrepancy
is unclear, but may also relate to the use of questionnaires in the VA
study to assess the presence of pulmonary disease, which has
a positive predictive power of only 58% to recognise COPD.16,17
Given the contrasting ﬁndings and the persistent controversy
with regard to the role of cigarette smoking in the association
between AAA and COPD, we considered a re-evaluation relevant.
The choice for PAD patients as the control population was based on
the parallels in risk factors between AAA and PAD, which not only
include dominance of smoking as the primary risk factor but also
other common non-modiﬁable risk factors such as age and male
gender.14 As more than 85% of both populations were former or
current smokers, with a similar burden of PYs, a considerable
proportion of patients with pulmonary impairment was expected
in both groups. However, signiﬁcantlymore airway obstructionwas
present in aneurysm patients, indicating that the high prevalence
of COPD is not explained by smoking alone. This observation
suggests that the relation between AAA and COPD reﬂects
a common susceptibility, a notion that is supported by converging
pathophysiologic pathways including metallopeptidase-9 and
neutrophil elastase.18,19 Such a common predisposition is suggested
by the observation that the difference in FEV1/FVC ratio between
AAA and PAD patients was most pronounced in never smokers.
Identiﬁcation of common mechanisms or pathways might be
highly relevant for future aneurysm and pulmonary research and
research collaboration initiatives. In our opinion, further investi-
gation of common genetic, inﬂammatory and remodelling path-
ways is warranted.
In line with two previous observations, we found no relation-
ship between the presence of obstructive pulmonary disease and
expansion of aneurysm diameter.9,20 Whether aneurysm growth is
related to an actual decline in FEV1 values can, however, not be
determined with this study. To that end, a long-term prospective
study design would be required including a much larger sample of
aneurysm patients, assessing pulmonary changes over time.2
This study has limitations. First, we performed a caseecontrol
study designed to overcome restraints of previous reports.
However, like all observational studies, our results are also subject
to bias from confounding factors. We matched both cohorts to
reduce imbalance with respect to smoking as the most apparent
confounding factor. Yet, small but signiﬁcant differences with
regard to potential confounders remained between the groups. We
mathematically adjusted for these potential confounders. Results
for this analysis showed that these adjustments only minimally
affected the results. Second, we used a 2.5 to 1 ratio for cases and
controls. This ratio was based on the power calculations for the
study. Although the signiﬁcant outcomes conﬁrm the adequacy of
the power calculation, a larger control groupwould have resulted in
smaller conﬁdence intervals.
Third, we used ﬁxed ratios and cut-off points to determine
obstructive pulmonary defects for reasons of simplicity and
comparability. While this is a common approach, this may result in
over-diagnosis in elderly patients because of the variable nature of
obstructive pulmonary diseases and the heterogeneity among
patients. Although COPD is operationally deﬁned by results on
spirometry, an adequate diagnostic process should include post-
bronchodilator spirometry, questionnaires and other clinical,
physiological and radiologic measures. It is clear that FEV1
measures and indices alone have epidemiological value but they are
not sufﬁcient for clinical decision-making.2
Finally, we would consider an additional histopathological
analysis of matched aneurysmal and pulmonary tissues from AAA
C.A. Meijer et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 153e157 157patients highly relevant. Yet, such a study would rely on tissues
obtained during post-mortems. Given the extremely low number of
post-mortem nowadays, such a study is extremely hard to conduct
and one has to rely on the abundance of literature on inﬂammatory
and proteolytic pathways in both conditions.3e5,18,19
Implications
Data from our clinical cohort show that 59% of COPD cases were
previously undetected; only 40 of the 98 detected AAA patients had
a diagnosis of COPD and received proper treatment. Spirometry
more than doubles the number of patients with a diagnosis of
COPD, indicating that COPD is under-diagnosed in the AAA
patients.21 This can be partially explained by low physical activity in
elderly patients, as symptoms of COPD such as shortness of breath
may remain unnoticed. These ﬁndings suggest that it is clinically
relevant to screen each AAA patient for obstructive pulmonary
disease.22 Early detection of COPD is useful, as appropriate disease
modiﬁcation is available. For COPD, the only approach that has
proven useful on modifying the course of the disease is smoking
cessation. However, the usefulness of long-acting beta agonists or
muscarinic antagonists in alleviation of the symptoms is also well
documented, thus enhancing quality of life.23 Moreover, COPD has
been identiﬁed as a co-morbidity associated with increased
cardiovascular risk and poor outcome for any major vascular
procedure.24,25 Appropriate preoperative care, with a detailed
respiratory assessment and careful attention to pulmonary function
in the postoperative period, is necessary to favour the post-
operative course of aneurysm patients.26
Conclusion
The ﬁndings of this study show that the increased prevalence of
COPD in patients with an AAA is independent from smoking.
In addition, COPD often remains unrecognised in aneurysm
patients.
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